Isofol Medical Past Earnings Performance
Past criteria checks 0/6
Isofol Medical has been growing earnings at an average annual rate of 3.3%, while the Biotechs industry saw earnings declining at 1.4% annually. Revenues have been growing at an average rate of 12.6% per year.
Key information
3.3%
Earnings growth rate
36.1%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | 12.6% |
Return on equity | -30.5% |
Net Margin | -5,141.6% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued
May 18Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation
Nov 09Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?
May 12Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)
Apr 08Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment
Mar 03We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully
Jan 10Revenue & Expenses BreakdownBeta
How Isofol Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -37 | 7 | 0 |
30 Sep 23 | 3 | -53 | 19 | 0 |
30 Jun 23 | 5 | -80 | 26 | 0 |
31 Mar 23 | 9 | -120 | 30 | 0 |
31 Dec 22 | 13 | -160 | 35 | 0 |
30 Sep 22 | 16 | -196 | 32 | 0 |
30 Jun 22 | 18 | -214 | 31 | 0 |
31 Mar 22 | 21 | -209 | 30 | 0 |
31 Dec 21 | 22 | -200 | 28 | 0 |
30 Sep 21 | 36 | -194 | 27 | 0 |
30 Jun 21 | 50 | -173 | 24 | 0 |
31 Mar 21 | 42 | -176 | 23 | 0 |
31 Dec 20 | 37 | -189 | 23 | 0 |
30 Sep 20 | 18 | -192 | 22 | 0 |
30 Jun 20 | 0 | -204 | -32 | 0 |
31 Mar 20 | 0 | -191 | -1 | 0 |
31 Dec 19 | 0 | -162 | 24 | 0 |
30 Sep 19 | 0 | -133 | 45 | 0 |
30 Jun 19 | 0 | -108 | 111 | 0 |
31 Mar 19 | 0 | -90 | 96 | 0 |
31 Dec 18 | 0 | -83 | 89 | 0 |
30 Sep 18 | 0 | -80 | 127 | 0 |
30 Jun 18 | 0 | -82 | 113 | 0 |
31 Mar 18 | 0 | -79 | 97 | 0 |
31 Dec 17 | 0 | -72 | 73 | 0 |
30 Sep 17 | 0 | -77 | 15 | 0 |
30 Jun 17 | 0 | -66 | 13 | 0 |
31 Mar 17 | 0 | -63 | 9 | 0 |
31 Dec 16 | 1 | -65 | 9 | 0 |
31 Dec 15 | 0 | -41 | 7 | 0 |
Quality Earnings: ISOFOL is currently unprofitable.
Growing Profit Margin: ISOFOL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ISOFOL is unprofitable, but has reduced losses over the past 5 years at a rate of 3.3% per year.
Accelerating Growth: Unable to compare ISOFOL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISOFOL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: ISOFOL has a negative Return on Equity (-30.53%), as it is currently unprofitable.